This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

ViewRay Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

ViewRay şirketinin toplam hissedar öz sermayesi $55.3M ve toplam borcu $77.8M olup, bu da borç-öz sermaye oranını 140.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $233.2M ve $177.9M dir.

Anahtar bilgiler

140.7%

Borç/özkaynak oranı

US$77.76m

Borç

Faiz karşılama oranı	n/a
Nakit	US$81.29m
Eşitlik	US$55.26m
Toplam yükümlülükler	US$177.90m
Toplam varlıklar	US$233.16m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6L9 'nin kısa vadeli varlıkları ( $193.6M ) kısa vadeli yükümlülüklerini ( $166.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6L9 şirketinin kısa vadeli varlıkları ( $193.6M ) uzun vadeli yükümlülüklerini ( $11.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6L9 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 6L9 şirketinin borç/öz sermaye oranı son 5 yılda 77.3% seviyesinden 140.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6L9 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 6L9 un, serbest nakit akışı her yıl % 2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company is no longer active

ViewRay Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

Motion for Joint Administration Filed by ViewRay, Inc.

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022)

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.67 loss in FY 2021)

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Insider recently bought €113k worth of stock

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2021)

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2021)

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought €379k worth of stock

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.17 loss in 1Q 2021)

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Insider recently bought €88k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought €88k worth of stock

Chief Financial Officer recently bought €181k worth of stock

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 1Q 2020)

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director has left the company

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million.

ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million.

New 90-day high: €4.22

New 90-day high: €3.68

New 90-day high: €3.26

President recently bought €423k worth of stock

Universitair Ziekenhuis Brussels Purchases ViewRay's MRIdian Linac

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

ViewRay, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high - €3.00

ViewRay, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço